Patients on PPIs more than twice as likely to develop gastric cancer, study finds
GPs must exercise caution when prescribing long-term PPIs as patients taking them are more than twice as likely to develop gastric cancer, a study has found.
Patients taking PPIs on a long-term basis were more likely to develop gastric cancer and the risk increased with both the strength of the dose and the duration of the treatment.
The study, conducted by researchers at the University of Hong Kong, looked at just over 63,000 patients who had been treated for H. pylori – a bacterium that can increase the risk of getting stomach cancer. Around 5% of these patients had been prescribed a PPI and patients were followed up for an average of 7.6 years.
They found that patients prescribed a PPI were 2.4 times as likely to develop gastric cancer as those who did not take PPIs. They also found that gastric cancer risk increased with the duration of therapy, with those taking a daily PPI for over a year having a five-fold increased risk, rising to just over eight-fold after three years.
Risk also increased based on the dose, with patients taking a weekly PPI being 2.4 times as likely as non-users to develop gastric cancer, rising to a 4.6-fold increased risk in those taking a daily PPI.
The authors said in the paper: 'Long-term use of PPIs in subjects with prior H. pylori eradication was still associated with an increased risk of gastric cancer development, particularly for non-cardiac cancer.
'There was also a clear dose–response and time–response trend of PPIs uses and gastric cancer risk. Physicians should therefore exercise caution when prescribing long-term PPIs to these patients even after successful eradication of H. pylori.'